# Real-world effectiveness of antibiotics in addition to oral corticosteroids for managing asthma exacerbations in adults

**Authors:** Irene Mommers, Sumaira Mubarik, Job F M van Boven, Jens H Bos, Maarten J Bijlsma, Eelko Hak

PMC · DOI: 10.1136/bmjresp-2025-003506 · BMJ Open Respiratory Research · 2025-10-20

## TL;DR

This study found that adding antibiotics to corticosteroids does not improve outcomes for adult asthma flare-ups, suggesting antibiotics should be avoided unless a bacterial infection is clear.

## Contribution

The study provides real-world evidence against the routine use of antibiotics for asthma exacerbations alongside corticosteroids.

## Key findings

- Adding antibiotics to corticosteroids did not reduce treatment failure in asthma exacerbations.
- There was no significant reduction in the risk of subsequent exacerbations with antibiotic use.
- Antibiotic use for asthma exacerbations declined from 47% in 2009 to 24% in 2020.

## Abstract

Antibiotics are widely used to manage acute asthma exacerbations, despite little evidence for their effectiveness. This study assesses the added value of antibiotics alongside oral corticosteroids (OCSs) in treating asthma exacerbations.

This retrospective cohort study included individuals from the Netherlands between 1994 and 2022 from the IADB.nl pharmacy dispensing database. Individuals had to be 16–45 years old, use inhaled asthma medication and have a first recorded prednisone/prednisolone (OCS) dispense of ≥30 mg/day for 3–14 days. Patients were compared regarding treatment failure (a new dispense of OCS or antibiotics, 15–30 days after initial dispense), based on whether or not they were dispensed antibiotics (AB) alongside their first recorded OCS dispense. Regression analyses with inverse probability of treatment weighting were used to adjust for various confounders.

Of the 5401 individuals included, 38% received antibiotics alongside the first-recorded OCS dispense, with a decreasing trend from 47% in 2009 to 24% in 2020. The OR for treatment failure was 1.36 (95% CI 0.81 to 2.16) for AB+OCS versus OCS-only. The HR for a new exacerbation within 31–365 days of follow-up was 1.20 (95% CI 0.92 to 1.56) for AB+OCS versus OCS-only. The lack of beneficial effect of AB was consistent across subcohorts.

This study found no reduction in treatment failure, nor in risk of subsequent exacerbation, from adding AB to OCS for treating acute asthma exacerbations. We suggest that antibiotics should not be used in primary care settings to treat acute asthma exacerbation unless there are clear signs of bacterial infection.

## Linked entities

- **Chemicals:** prednisone (PubChem CID 5865), prednisolone (PubChem CID 5755)
- **Diseases:** asthma (MONDO:0004979)

## Full-text entities

- **Diseases:** asthma (MESH:D001249), bacterial infection (MESH:D001424)
- **Chemicals:** OCS (-), prednisone (MESH:D011241), prednisolone (MESH:D011239)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12542710/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12542710/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12542710/full.md

---
Source: https://tomesphere.com/paper/PMC12542710